We are live on ! Find out more
REGN icon

Regeneron Pharmaceuticals

1,079 hedge funds and large institutions have $56.6B invested in Regeneron Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 175 funds opening new positions, 428 increasing their positions, 321 reducing their positions, and 97 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 175 | Existing positions closed: 97

33% more repeat investments, than reductions

Existing positions increased: 428 | Existing positions reduced: 321

6% more funds holding

Funds holding: 1,0171,079 (+62)

4% more capital invested

Capital invested by funds: $54.4B → $56.6B (+$2.25B)

0.66% less ownership

Funds ownership: 86.01%85.34% (-0.66%)

12% less funds holding in top 10

Funds holding in top 10: 1715 (-2)

33% less call options, than puts

Call options by funds: $985M | Put options by funds: $1.48B

Holders
1,079
Holders Change
+62
Holders Change %
+6.1%
% of All Funds
16.61%
Holding in Top 10
15
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-11.76%
% of All Funds
0.23%
New
175
Increased
428
Reduced
321
Closed
97
Calls
$985M
Puts
$1.48B
Net Calls
-$492M
Net Calls Change
-$207M
Name Holding Trade Value Shares
Change
Change in
Stake
PCM
601
Prelude Capital Management
New York
$723K +$199K +323 +39%
JSL
602
JT Stratford LLC
Georgia
$712K +$286K +465 +70%
MFG
603
MidWestOne Financial Group
Iowa
$704K +$80.5K +131 +13%
GC
604
Globeflex Capital
California
$704K +$496K +807 +262%
CAN
605
Claraphi Advisory Network
United States
$701K -$75K -122 -10%
SBH
606
Segall Bryant & Hamill
Illinois
$701K +$29.5K +48 +5%
PA
607
Parallel Advisors
California
$698K +$38.7K +63 +6%
PCS
608
Personal CFO Solutions
New Jersey
$698K +$282K +459 +71%
GIA
609
Gateway Investment Advisers
Ohio
$697K -$14.8K -24 -2%
APWA
610
Atlas Private Wealth Advisors
New Jersey
$693K +$4.92K +8 +0.7%
AHIA
611
Andrew Hill Investment Advisors
Florida
$688K +$671K +1,091 New
KPWS
612
Kestra Private Wealth Services
Texas
$686K +$280K +456 +72%
SIC
613
Salem Investment Counselors
North Carolina
$684K +$154K +250 +30%
CT
614
Chicago Trust
Illinois
$680K
IFWM
615
Institute for Wealth Management
Colorado
$676K
CIM
616
CIM Investment Management
Pennsylvania
$671K -$11.7K -19 -2%
VAFP
617
Vahanian & Associates Financial Planning
New York
$666K +$648K +1,054 New
FF
618
FourThought Financial
Florida
$664K -$185K -301 -22%
PIM
619
Penobscot Investment Management
Massachusetts
$662K +$76.2K +124 +13%
HIM
620
Hillsdale Investment Management
Ontario, Canada
$657K +$639K +1,040 New
CTA
621
Chesley Taft & Associates
Illinois
$650K +$65.2K +106 +11%
PFO
622
Pathstone Family Office
New Jersey
$649K +$339K +552 +116%
SDIC
623
South Dakota Investment Council
South Dakota
$647K -$492K -800 -44%
Verition Fund Management
624
Verition Fund Management
Connecticut
$646K -$282K -459 -31%
JIC
625
Johnson Investment Counsel
Ohio
$645K -$3.07K -5 -0.5%

REGN Hedge Fund Activity: Q4 2021 in Review

1,079 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2021, worth a combined $56.6B — up 4.1% from $54.4B a quarter earlier.

Buyers outnumbered sellers: 175 funds opened new REGN positions and 97 closed out — a net gain of 78 holders — while 428 added to existing stakes and 321 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $301M. The largest seller was Fidelity Investments, cutting an estimated $618M.

  • 1,079 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2021, up from 1,017 in Q3 2021.
  • Funds reported $56.6B of Regeneron Pharmaceuticals stock for Q4 2021, up 4.1% quarter-over-quarter.
  • 175 funds opened new Regeneron Pharmaceuticals positions in Q4 2021 and 97 closed out, a net change of +78 holders.
  • The largest Regeneron Pharmaceuticals buyer in Q4 2021 was JP Morgan Chase, an estimated $301M added.
  • The largest Regeneron Pharmaceuticals seller in Q4 2021 was Fidelity Investments, an estimated $618M sold.

Based on aggregated 13F filings for Q4 2021.